Precision BioSciences vs Editas Medicine
DTIL and EDIT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DTIL and EDIT compare
Editas Medicine is the larger company, worth 1.4 times as much as Precision BioSciences ($366M against $253M).
Precision BioSciences grew revenue faster over the last twelve months (6353% versus 7.4% for Editas Medicine).
Precision BioSciences keeps more of each dollar of sales as profit, with a net margin of −85.6% compared with −145% at Editas Medicine.
Precision BioSciences scores higher on the StockData Score (4 against 3 for Editas Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DTIL | EDIT |
|---|---|---|
| Size and price | ||
| Market cap | $253M | $366M |
| Share price | $9.15 | $2.38 |
| Change, 1 year | 50.7% | −5.6% |
| Change, 5 years | −96.7% | −93.3% |
| Beta (5Y) | 1.30 | 2.19 |
| Employees | 68 | 87 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.6× (better) | 7.3× |
| P/B | 4.9× | 4.3× (better) |
| FCF yield | −20.5% (better) | −30.2% |
| Fair value | $4.64 | $1.62 |
| Margin of safety | −97.4% | −47.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 6353% (better) | 7.4% |
| Revenue growth, 5Y average | 7.1% (better) | −14.9% |
| Profitability | ||
| Operating margin | −80.3% (better) | −152% |
| Net margin | −85.6% (better) | −145% |
| FCF margin | −115% (better) | −222% |
| Return on equity | −113% (better) | −147% |
| Financial health | ||
| Debt / equity | – | 0.67 |
| Interest coverage | −28.6× | −10.6× (better) |
| Current ratio | 10.47 (better) | 2.82 |
| Altman Z-score | −4.45 (better) | −9.39 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −36.6% |
| Shareholder yield | 0.00% (better) | −36.6% |
| Ownership | ||
| Held by institutions | 64.0% | 78.3% |
| Held by insiders | 3.0% | 0.45% |
| Insider net buying, 12 months | −$368K | −$107K (better) |
| Short interest, % of float | 7.8% | 25.3% |
Go deeper
- DTIL stock overview
- DTIL income statement
- DTIL valuation and score
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.